Q4: 2026-03-05 Earnings Summary
EPS of -$0.27 misses by $0.03
| Revenue of $26.00K (420.00% Y/Y) beats by $25.44K
Altimmune, Inc. (ALT) Barclays 28th Annual Global Healthcare Conference March 12, 2026 10:30 AM EDT
Company Participants
Jerome Durso – Chairman, CEO & President
Gregory Weaver – Chief Financial Officer
Christophe Arbet-Engels – Chief Medical Officer
Conference Call Participants
Eliana Merle – Barclays Bank PLC, Research Division
Presentation
Eliana Merle
Barclays Bank PLC, Research Division
Hi. Good morning, everyone. I’m Ellie Merle, one of the biotech analysts here at Barclays. Very happy to have Altimmune here with us for a fireside chat. Joining us from Altimmune, we have Jerry Durso, Chief Executive Officer; Christophe Arbet-Engels, sorry, if I butchered your name, Chief Medical Officer; and Greg Weaver, Chief Financial Officer. Thank you all so much for joining us.
Jerome Durso
Chairman, CEO & President
Happy to be here.
Question-and-Answer Session
Eliana Merle
Barclays Bank PLC, Research Division
To begin, maybe if we could start with a brief overview of the key highlights of Altimmune’s progress over 2025 and into the first quarter of ’26, including on the financial front as well.
Jerome Durso
Chairman, CEO & President
Sure. So we’ve been busy as a company and a lot going on and really an exciting year ahead of us in 2026. Last year, significant progress on the clinical side. The Phase II MASH trial read out in 2 different time periods. We had the 24 data — 24-week data that came out in June and then right at the end of the year in December, the 48-week data set. I think we got a really good view of the potential target product profile on pemvidutide in MASH. I think the 48-week data really reinforces what we may expect to see in the same time frame that we’re designing the Phase III trial.
I know we’ll go into some details on that, but really starting
Read the full article here
